Previous Article | Next Article 
Journal of Virology, September 1998, p. 7653-7658, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Lipofection of Purified Adeno-Associated Virus
Rep68 Protein: toward a Chromosome-Targeting Nonviral
Particle
Stefania
Lamartina,
Giuseppe
Roscilli,
Daniela
Rinaudo,
Paola
Delmastro, and
Carlo
Toniatti*
Department of Genetics, Istituto di Ricerche
di Biologia Molecolare, I.R.B.M.
Piero Angeletti, 00040 Pomezia,
Rome, Italy
Received 5 February 1998/Accepted 3 June 1998
 |
ABSTRACT |
Adeno-associated virus (AAV) integrates very efficiently into a
specific site (AAVS1) of human chromosome 19. Two elements of the AAV
genome are sufficient: the inverted terminal repeats (ITRs) and the
Rep78 or Rep68 protein. The incorporation of the AAV integration
machinery in nonviral delivery systems is of great interest for gene
therapy. We demonstrate that purified recombinant Rep68 protein is
functionally active when directly delivered into human cells by using
the polycationic liposome Lipofectamine, promoting the
rescue-replication of a codelivered ITR-flanked cassette in
adenovirus-infected cells and its site-specific integration in
noninfected cells. The sequencing of cloned virus-host DNA junctions
confirmed that lipofected Rep68 protein triggers site-specific integration at the same sites in chromosome 19 already characterized in
cells latently infected with AAV.
 |
TEXT |
Adeno-associated virus (AAV) is a
defective parvovirus with a single-stranded DNA genome of 4.7 kb
comprising two open reading frames coding for nonstructural (Rep) and
structural (Cap) proteins, and the entire genome is flanked by two
identical 145-base inverted terminal repeats (ITRs) (3). AAV
replicates only in cells coinfected by a helper virus such as
adenovirus (Ad); in the absence of coinfection, the virus integrates
stably into a defined region, called AAVS1, of human chromosome 19 (q13.4-qter) (9, 16, 17, 27, 29).
The mechanism of AAV integration has been partially elucidated. The two
hairpinned ITRs are the minimal elements required for integration; in
fact, recombinant AAV vectors lacking the rep and
cap genes still integrate into the human genome, albeit not
specifically in chromosome 19 (6, 15, 39). The efficiency of
ITR-dependent integration is presently unknown (39).
Integration into the AAVS1 site also requires the presence of the viral
Rep78 or Rep68 protein (6, 23). Rep78 and Rep68 are
expressed from unspliced and spliced transcripts, respectively,
initiated at the common p5 promoter (3). The two proteins
have similar biochemical properties: they bind to a specific DNA
sequence (the Rep binding site [RBS]) present in the AAV ITRs and the
p5 promoter, nick the terminal resolution site (trs) in the
ITRs in a strand- and site-specific manner, and have an ATP-dependent
helicase activity (11, 12). The first step in site-specific
integration is postulated to be the formation of a complex, mediated by
Rep78 or Rep68, between the AAV ITR and an RBS which has been
identified within the AAVS1 site (37). Subsequently,
integration is presumed to proceed through a replication-mediated
recombination process, in which several template switches occur during
synthesis of new DNA strands; the entire process requires the activity
of the cellular factors involved in DNA replication and repair
(22).
The use of elements of AAV to drive site-specific integration of
exogenous DNA sequences delivered with nonviral systems is of great
interest for gene therapy (6, 21). In fact, one of the major
problems associated with nonviral delivery, the transient expression of
the transgene due to the rapid degradation of delivered DNA, might be
overcome by utilizing viral components that facilitate integration of
the transgene into the host genome. The feasibility of this approach
has been demonstrated recently: expression vectors for either Rep78 or
Rep68 can promote the integration into the AAVS1 site of an ITR-flanked
transgene delivered either in the same plasmid or in a cotransfected
plasmid (1, 31, 34). The advantages of nonviral delivery are
that no potentially replicating viruses are introduced and that, in
theory, there would be no size constraint for the integrating sequence.
Cationic liposomes currently represent one of the most promising tools
for nonviral delivery in gene therapy, and a great deal of work is
being devoted to enhancing their efficacy in vivo (5, 8, 18, 19,
24, 35). Although they are used mainly for introducing DNA, they can also deliver proteins or peptides in vitro and in vivo (2, 7,
13, 14, 20, 30, 40). As a first step toward the assembling of an
"ideal" nonviral particle incorporating the AAV integration
machinery, we thus decided to test the hypothesis that functionally
active (i.e., integration-competent) Rep78 or Rep68 recombinant protein
could be delivered into cultured cells by using cationic liposomes.
Before determining whether a functional recombinant Rep78
or Rep68 could be lipofected into cells, we tested whether the
two genes promote site-specific integration with the same efficiency. Three different plasmids were constructed. The first construct, ITR/Hook-Neo (Fig. 1), contains an
"integration element," represented by the expression cassette
for the neomycin resistance gene (Neo) and the expression cassette for
the membrane-bound single-chain antibody, both cloned between the AAV
ITRs contained in vector pSub201 (28). From ITR/Hook-Neo,
two plasmids, called 78/ITR/Hook-Neo and 68/ITR/Hook-Neo, were derived;
these contain, outside the ITR-flanked cassettes and under the control
of the cytomegalovirus (CMV) enhancer/promoter element, cDNAs for Rep78
and Rep68, respectively (Fig. 1). Western blotting performed with
whole-cell extracts from transiently transfected HeLa cells confirmed
that only Rep78 and Rep68 were produced from plasmids 78/ITR/Hook-Neo
and 68/ITR/Hook-Neo, respectively (data not shown).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 1.
Site-specific integration in HeLa cell clones.
Transfected plasmids are schematically represented. Black boxes
represent the AAV ITRs flanking the Hook and Neo expression
cassettes. The Neo gene was derived from plasmid PRc/RSV, and the Hook
gene was obtained from plasmid pHook-1 (both from Invitrogen). The
individual cDNAs coding for Rep78 and Rep68 were obtained by
site-directed mutagenesis of the Rep open reading frame (nucleotides
320 to 2252 of the AAV genome [33]) as described
elsewhere (34). Integration at the AAVS1 site was assessed
by DNA hybridization analysis with AAVS1 and neo-specific
probes as described in the text.
|
|
Plasmid ITR/Hook-Neo and its two Rep-expressing derivatives were
transfected into HeLa cells by the calcium phosphate technique: following 14 to 18 days of growth in selective medium containing 700 µg of G418/ml, 37 single-cell-derived neomycin-resistant clones were
isolated and expanded. Genomic DNA was extracted, digested with the
restriction enzyme BamHI, which has no recognition site in
the transgene and in the subregion of AAVS1 in which the great majority
of integration events are detected (17, 39), and analyzed by
Southern blotting using probes specific for AAVS1 and for the
neo gene. Two criteria were adopted to monitor site-specific integration: the detection, by using the AAVS1 probe, of an upshifted band with respect to the normal AAVS1 site present in the parental cell
line and the cohybridization of the same band with the Neo probe.
According to this scoring system, no site-specific integration was
detected in cells transfected with plasmid ITR/Hook-Neo; in contrast,
integration in AAVS1 was evident in clones derived from cells
transfected with the Rep-expressing plasmids. As summarized in Fig. 1,
similar percentages of site-specific integration were observed for
constructs expressing Rep78 and those expressing Rep68 (24% for
78/ITR/Hook-Neo and 22% for 68/ITR/Hook-Neo). This demonstrates that
the two Rep proteins mediate integration in the AAVS1 site with similar
efficiencies. We thus decided to investigate integration using the
smaller of the two proteins, Rep68.
Rep68 protein was expressed in Escherichia coli and purified
to homogeneity (Fig. 2). Its
functionality was checked by testing its capability to bind to and
cleave AAV ITRs and to support AAV DNA replication in vitro (data not
shown). To test whether Rep68 could be lipofected in cells, we used
Lipofectamine, a commercially available liposome preparation consisting
of a 3:1 (wt/wt) mixture of the polycationic lipid
2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propaminium trifluoroacetate (DOSPA) and the neutral lipid dioleoyl
phosphatidylethanolamine (DOPE). Five micrograms of Rep68 was mixed
with 10 µg of Lipofectamine in a total volume of 200 µl of Optimem;
following 30 min of incubation, 800 µl of Optimem was added and the
mixture was layered on 2 × 105 human renal carcinoma
293 cells. In control experiments, cells were incubated with Rep68
alone. After 2 h, the intracellular distribution of Rep68 was
visualized by indirect immunofluorescence with an anti-Rep monoclonal
antibody. No signal was observed in cells incubated with Rep68 alone;
only a small percentage of cells (about 2 to 3%) displayed the faint
and diffuse staining shown in Fig. 2B. In contrast, Rep68 was clearly
visible in the nuclei of cells transfected with the
Rep68-Lipofectamine complex (Fig. 2C); in different experiments, the
efficiency of transfection, measured as the percentage of positively
stained cells, ranged from 20 to 40%. This result demonstrates that
the lipofected protein efficiently enters the cells and undergoes a
physiological cytoplasm-to-nucleus transport. A strong signal was also
observed at 4 and 8 h posttransfection, while after 1 and 2 days,
the number of positive cells strongly decreased. Similar results were
obtained with the adenocarcinoma-derived cell line HeLa and the
hepatocarcinoma-derived cell lines HuH7 and Hep3B (data not shown). It
is worth noting that during the 2 days of these experiments, we did not
observe any obvious phenotypic difference between cells (293, HeLa,
Hep3B, and HuH7) lipofected with Rep68 protein and cells transfected
with a Rep68 expression vector. Experiments were also designed to
monitor the stability of delivered protein: Western blotting
experiments, performed by probing whole-cell extracts prepared at
different times postlipofection with an anti-Rep68 polyclonal serum,
demonstrated that lipofected Rep68 undergoes progressive proteolytic
degradation according to a kinetics which parallels, and therefore
accounts for, the gradual decrease of the nuclear signal observed in
immunofluorescence experiments (data not shown).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 2.
Lipofection of Rep68 protein. (A) Silver staining of a
sodium dodecyl sulfate-polyacrylamide gel. Rep68 protein was expressed
in E. coli as a fusion protein with maltose binding protein
(MBP) as described elsewhere (4) and was partially purified
by amylose affinity chromatography (lane 1), cleaved with Factor Xa to
remove the maltose-binding moiety, and purified to homogeneity (lane 2)
by fast protein liquid chromatography with MonoQ (anion exchange) and
Superdex-75 (gel filtration) columns (both from Pharmacia). M,
molecular size markers. (B and C) Intracellular localization of
lipofected Rep68 protein. Two hours after transfection, 293 cells were
washed, fixed in 3% formaldehyde, and permeabilized by treatment with
0.1% Triton X-100. The intracellular location of Rep68 was monitored
by sequential incubation with the mouse monoclonal anti-Rep
antibody 226.7 (Progen) and a rhodamine-conjugated anti-mouse
immunoglobulin G goat polyclonal serum. Shown are results of staining
of cells incubated for 2 h with Rep68 alone (B) or with the
Rep68-Lipofectamine complex (C).
|
|
To test whether intranuclear Rep68 retained its biochemical properties,
nuclear extracts were prepared 2 h after lipofection of 293 cells
with Rep68 and incubated in the standard trs endonuclease reaction with labelled AAV ITR as described elsewhere (32). As a control, extracts from cells lipofected with the expression vector
pCMVrep68, containing the cDNA for Rep68 cloned downstream of the CMV
enhancer/promoter, were tested. Figure 3
shows that a site- and strand-specific nicking activity was detected
only in the nuclear extracts of cells either lipofected with Rep68 (lanes 7 and 8) or transfected with the Rep68 expression vector (lanes
5 and 6): no specific activity was detected in untransfected cells
(lanes 3 and 4).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Endonuclease reaction with nuclear extracts of cells
lipofected with Rep68 protein. Ten thousand counts per minute of
trs+ hairpin substrate that had been 5'-end labelled with
32P, prepared as described elsewhere (32), was
incubated for 1 h in endonuclease assay buffer (32)
with 1 and 3 µg of nuclear extracts from untransfected cells (lanes 3 and 4, respectively), cells lipofected with the Rep68 expression vector
pCMVrep68 (lanes 5 and 6), or cells lipofected with Rep68 protein
(lanes 7 and 8). A standard endonuclease reaction was carried out
(32). The reaction was terminated by treatment with
proteinase K, phenol extraction, and ethanol precipitation; samples
were then resolved on an 8% polyacrylamide sequencing gel. The
position of the 73-base product of the nicking reaction is indicated on
the right. In lane 1, the starting trs+ substrate was
loaded. Lane 2 shows the results of a control experiment with 10 ng of
purified Rep68. Nuclear extracts were prepared as described elsewhere
(36).
|
|
To further verify the functionality of the lipofected Rep68, we tested
its capability to stimulate, in Ad-infected cells, the
rescue-replication of an ITR-flanked cassette contained in a
codelivered recombinant plasmid (28). Two cell lines were used: HeLa and HepG2. In both cases, 7.5 µg of plasmid ITR/Hook-Neo and increasing concentrations of Rep68 were coincubated in 1.8 ml of
Optimem with 60 µg of Lipofectamine; after 30 min, 7.2 ml of
medium was added and the mixture was layered on 2 × 106 cells which had been infected 2 h before with Ad-2
at a multiplicity of infection of 10. In control experiments, the same
plasmid ITR/Hook-Neo was mixed with equivalent amounts of the pCMVrep68
expression vector or a carrier plasmid. After 8 h of incubation,
medium was changed and cells were grown for additional 60 h.
Low-molecular weight DNA was then isolated according to Hirt's
procedure (10), digested extensively with DpnI to
eliminate unreplicated input plasmid DNA (38), and then
analyzed by Southern blotting with a neo probe. As shown in
Fig. 4, a Rep68-dose-dependent increase in the amount of rescued and replicated DNA was observed in both HeLa
(Fig. 4A) and HepG2 cells (Fig. 4B). The signal corresponding to the
rescued monomer was clearly detected with 4 µg of Rep68 protein (Fig.
4, lanes 6) and reached a plateau when 16 µg of the protein was
lipofected (Fig. 4, lanes 8). As expected, no signal was detected in
the absence of Rep (Fig. 4, lanes 2), while strong rescue-replication
occurred in cells transfected with the Rep68 expression vector (Fig. 4,
lane 1). Similar results were obtained with 293 cells (data not shown).

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 4.
Southern blot analysis of rescue-replication from
plasmid ITR/Hook-Neo in Ad-infected cells lipofected with Rep68
protein. Rescue-replication assays were performed in HeLa (A) and HepG2
(B) cells. In both cases, cells were lipofected with 7.5 µg of
plasmid ITR/Hook-Neo in combination with either an equivalent
amount of pCMVrep68 expression vector (lanes 1) or increasing
concentrations (0.5, 1, 2, 4, 8, 16, and 32 µg) of Rep68 protein
(lanes 3, 4, 5, 6, 7, 8, and 9, respectively). As a control, DNA
was extracted from cells transfected only with the ITR/Hook-Neo
plasmid (lanes 2). Equivalent amounts of low-Mr
DNA samples isolated at 68 h posttransfection were digested
with DpnI, electrophoresed on agarose gels, and analyzed on
Southern blots with a neo probe. The arrows on the left
indicate the rescued monomer; dimeric forms were also observed after
longer exposure (data not shown). Molecular sizes are shown in
kilobases.
|
|
In subsequent experiments we used a nested-set PCR assay to monitor the
capability of recombinant Rep68 to promote site-specific integration.
Sixteen micrograms of Rep was lipofected along with 7.5 µg of
ITR/Hook-Neo into HeLa cells as described above. In control
experiments, cells were lipofected with 7.5 µg of plasmid ITR/Hook-Neo alone or in combination with 7.5 µg of the Rep68 expression vector pCMVrep68. After 48 h, cells were collected, and
genomic DNA was extracted and used as a template for a PCR using primers designed to flank the ITR-AAVS1 junction (a scheme of the
assay is shown in Fig. 5C). A first amplification was carried out with
one ITR-specific primer (p1, 5'-GTAGCATGGCGGGTTAATCA-3') and
one AAVS1-specific primer (p2, 5'-GCGCGCAGAAGCCAGTAGAGC-3') by using AmpliTaq Gold (Perkin-Elmer) polymerase according to the
manufacturer's instructions in a total volume of 50 µl. The reaction
proceeded for 25 cycles (1 min at 94°C, 1 min at 60°C, and 2 min at
72°C). Ten microliters of the amplification product was then used as
a template for a second round of PCR, performed exactly like the first
one but using the ITR-specific primer p3 (5'-TTAACTACAAGGAACCCCTAGTGATGG-3') and the
AAVS1-specific primer p4 (5'-GATAGACCAGACCTGAGCTATGGGAG-3').
The amplification product from the second round was run on an
agarose gel, blotted, and hybridized with AAVS1-derived as well as
ITR-derived probes; signals detected with both probes were considered
to be derived from specific amplification of ITR-AAVS1 junctions and
therefore were scored as true integration events. Figure
5 shows
that no signal was detected in untransfected cells (Fig. 5A and B,
lanes 4) or those transfected with the ITR/Hook-Neo plasmid alone (Fig.
5A and B, lanes 2); in contrast, positive signals, i.e., site-specific
integration events, were observed in cells lipofected with ITR/Hook-Neo
and the Rep68 protein (Fig. 5A and B, lanes 3). As expected,
integration was also observed in cells transfected with the ITR-flanked
cassette and the Rep68 expression vector (Fig. 5A and B, lanes 1).
Similar results were obtained with 293 and HuH7 cells and when Rep78
expression vectors were used (data not shown). In cells transfected
with the Rep expression vector, the positive signal appeared as a smear on the agarose gel, in line with the observation that site-specific integration can take place in a region spanning at least 500 bp of
human chromosome 19, and therefore the amplified ITR-AAVS1 junctions
are expected to be heterogeneous in size (38). The positive
signal obtained with lipofected Rep68 had a reproducibly different
pattern: in this case, one to three major bands (depending on the
experiment) were observed in the context of a faint smear. This might
indicate that the protein-mediated integration is clustered in a more
limited number of sites within AAVS1; more likely, however, the result
might reflect a lower intracellular level of Rep68 when the protein,
instead of an expression vector, is delivered.

View larger version (79K):
[in this window]
[in a new window]

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Lipofected Rep68 protein mediates site-specific
integration into AAVS1. (A and B) Southern blot analysis of PCR
amplification products generated from ITR-AAVS1 junctions. (A)
Hybridization with the AAVS1 probe; (B) hybridization with the ITR
probe. PCRs were carried out by using as a template the genomic
DNA isolated from HeLa cells 48 h after lipofection with plasmid
ITR/Hook-Neo alone (lanes 2) or in combination with the pCMVrep68
expression vector (lanes 1) or with Rep68 protein (lanes 3). Control
reactions were performed with DNA extracted from untransfected cells
(lanes 4). Amplification products were blotted onto nylon membranes;
the same filter was probed first with a 32P-labelled
AAVS1-specific probe (spanning nucleotides 210 to 1140 of the published
AAVS1 sequence [17]) and then, after stripping, with
an ITR-specific probe, excised as an MscI-PvuII
fragment from plasmid pSub201 (28). (C) Sequence analysis of
ITR-AAVS1 junctions. At the top is a schematic representation of
the PCR assay. The sequence of one strand of the ITRs in plasmid
ITR/Hook-Neo, in the "flop" orientation (3, 27), is
shown; the nucleotide numbering is relative to the right end of the AAV
genome (33). Letters (D, A, B, B', C, C', and A') indicate
palindromic sequences. Junctions obtained with the Rep68 proteins
(r68-1 through -4) and with the pCMVrep68 expression vector (p68-1
through -6) are shown below the PCR assay representation. The numbers
of the last evident cellular and viral nucleotides are given. AAVS1
breakpoints are based on the published AAVS1 sequence (17).
Overlapping sequences between the ITR and AAVS1 are underlined.
Insertions between the ITR and AAVS1 breakpoints are boldfaced.
|
|
We also cloned and sequenced those PCR products which not only
cohybridized with AAVS1 and ITR probes but also were detected by direct
ethidium bromide staining of the gels. Three junctions generated in
HeLa cells lipofected with the integration cassette and recombinant
Rep68 were sequenced; they are shown in Fig. 5C. The insertion of the
ITR-flanked cassette occurred within a 16-bp region of the AAVS1 site
mapping at nucleotides 1016 to 1032 of the published AAVS1 sequence
(17), while the ITR breakpoints occurred in the A (junctions
r68-2 and -3) and B (junction r68-1) regions of the terminal repeat.
Six junctions generated in cells lipofected with the integration
cassette and the Rep68 expression vector were also sequenced (junctions
p68-1 through -6 [Fig. 5C]). In this case, the breakpoints in
chromosome 19 were located in a larger region spanning about 500 bp,
from nucleotide 842 (junction p68-2) to nucleotide 1295 (junction
p68-1) of the AAVS1 sequence. It is worth noting that the location of
all these junction breakpoints closely resembles that of the virus-cell
junctions characterized in cells latently infected with AAV (29,
39). As for all the AAV-cell junctions analyzed so far, in this
case, too, a complete ITR was never detected. In addition, the finding
of two junctions, p68-5 and p68-6, containing the ITR in the "flip"
orientation, the opposite of the "flop" orientation of the ITRs
present in the transfected plasmid (Fig. 5C), strongly supports the
hypothesis that plasmid integration, like the integration of wild-type
AAV, proceeds through intermediate steps of replication of the plasmid template (22, 33).
The expression time of transgenes delivered via nonviral particles such
as liposomes might be prolonged by promoting their integration into the
host genome. In addition, the use of AAV elements to specifically
target the AAVS1 site in human chromosome 19 should minimize the risk
of insertional mutagenesis. In relation to this point, the observation
that liposome-delivered Rep68 protein promotes the site-specific
integration of a codelivered ITR-flanked cassette is of great interest.
In fact, lipofection of the Rep68 protein, instead of Rep78 or Rep68
expression vectors, might temporally limit the activity of the protein
until its degradation takes place; this could prevent undesired
effects, such as the described rearrangements at the AAVS1 site
following the integration event (1, 33, 39), possibly a
consequence of prolonged expression of the Rep proteins. Utilizing
recombinant Rep68 would also eliminate the potential problem of the
integration of the rep gene, which has been reported to take
place (34). In addition, lipofection of Rep68 protein might
increase the specificity of integration; in fact, the assembling of
liposomes containing preformed complexes between Rep68 and AAV ITRs
could prevent the random insertion of the integration cassette
(39), which, when a Rep78 or Rep68 expression vectors is
used, would take place until a sufficient quantity of Rep78 or Rep68 is
produced. In this connection, it is worth noting that in AAV particles,
the Rep78 protein is covalently linked to the packaged genome and that,
following infection of cells, a significant portion of the viral
single-stranded DNA remains attached to Rep78 after nuclear
translocation (25, 26).
In conclusion, the demonstration that AAV Rep68 protein is functional
when lipofected into cells represents a first step toward the
construction of nonviral particles able to promote site-specific integration of the desired transgene. Future work will be devoted to
optimizing this system and further validating the utility of this
approach.
 |
ACKNOWLEDGMENTS |
We thank Gennaro Ciliberto and Nicola La Monica for critically
reading the manuscript. We also gratefully acknowledge Janet Clench for
editing the manuscript and M. Emili for graphics work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Istituto di
Ricerche di Biologia Molecolare, I.R.B.M.
P.Angeletti, Via Pontina Km
30,600, 00040 Pomezia, Rome, Italy. Phone: 39-6-91093668. Fax:
39-6-91093654. E-mail: toniatti{at}irbm.it.
 |
REFERENCES |
| 1.
|
Balagué, C.,
M. Kalla, and W.-W. Zhang.
1997.
Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome.
J. Virol.
71:3299-3306[Abstract].
|
| 2.
|
Baubonis, W., and B. Sauer.
1993.
Genomic targeting with purified Cre recombinase.
Nucleic Acids Res.
21:2025-2029[Abstract/Free Full Text].
|
| 3.
|
Berns, K. I., and R. M. Linden.
1995.
The cryptic life style of adeno-associated virus.
Bioessays
17:237-245[Medline].
|
| 4.
|
Chiorini, J. A.,
M. D. Weitzman,
R. A. Owens,
E. Urcelay,
B. Safer, and R. M. Kotin.
1994.
Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli.
J. Virol.
68:797-804[Abstract/Free Full Text].
|
| 5.
|
Deshnukh, H. M., and L. Huang.
1997.
Liposome and polylysine mediated gene transfer.
New J. Chem.
21:113-124.
|
| 6.
|
Flotte, T. R., and B. J. Carter.
1995.
Adeno-associated virus vectors for gene therapy.
Gene Ther.
2:357-362[Medline].
|
| 7.
|
Gao, X., and L. Huang.
1993.
Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes.
Nucleic Acids Res.
21:2867-2872[Abstract/Free Full Text].
|
| 8.
|
Gao, X., and L. Huang.
1995.
Cationic liposome-mediated gene transfer.
Gene Ther.
2:710-722[Medline].
|
| 9.
|
Giraud, C.,
E. Winocour, and K. I. Berns.
1994.
Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence.
Proc. Natl. Acad. Sci. USA
91:10039-10043[Abstract/Free Full Text].
|
| 10.
|
Hirt, B.
1967.
Selective extraction of polyoma DNA from infected mouse cell cultures.
J. Mol. Biol.
26:365-369[Medline].
|
| 11.
|
Im, D.-S., and N. Muzyczka.
1990.
The AAV origin-binding protein Rep68 is an ATP dependent site-specific endonuclease with DNA helicase activity.
Cell
61:447-457[Medline].
|
| 12.
|
Im, D.-S., and N. Muzyczka.
1992.
Partial purification of adeno-associated virus Rep78, Rep68, Rep52, and Rep40 and their biochemical characterization.
J. Virol.
66:1119-1128[Abstract/Free Full Text].
|
| 13.
|
Kaneda, Y.,
K. Iwai, and T. Uchida.
1989.
Increased expression of DNA cointroduced with nuclear protein in adult liver.
Science
243:375-378[Abstract/Free Full Text].
|
| 14.
|
Kato, K.,
M. Nakanishi,
Y. Kaneda,
T. Uchida, and Y. Okada.
1993.
Expression of hepatitis B virus surface antigen in adult rat liver: cointroduction of DNA and nuclear protein by a simplified liposome method.
J. Biol. Chem.
266:3361-3364[Abstract/Free Full Text].
|
| 15.
|
Kearns, W. G.,
S. A. Afione,
S. B. Fulmer,
M. G. Pang,
D. Erikson,
M. Egan,
M. J. Landrum,
T. R. Flotte, and G. R. Cutting.
1996.
Recombinant adeno-associated (AAV-CTFR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.
Gene Ther.
3:748-755[Medline].
|
| 16.
|
Kotin, R. M.,
M. Siniscalco,
R. J. Samulski,
X. D. Zhu,
L. Hunter,
C. A. Laughlin,
S. M. Laughlin,
N. Muzyczka,
M. Rocchi, and K. I. Berns.
1990.
Site-specific integration by adeno-associated virus.
Proc. Natl. Acad. Sci. USA
87:2211-2215[Abstract/Free Full Text].
|
| 17.
|
Kotin, R. M.,
R. M. Linden, and K. I. Berns.
1992.
Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination.
EMBO J.
11:5071-5078[Medline].
|
| 18.
|
Lasic, D. D., and N. S. Templeton.
1996.
Liposomes in gene therapy.
Adv. Drug Delivery Rev.
20:221-266.
|
| 19.
|
Ledley, F. D.
1995.
Nonviral gene therapy: the promise of genes as pharmaceutical products.
Hum. Gene Ther.
6:1129-1144[Medline].
|
| 20.
|
Lee, K.-D.,
Y. K. Oh,
D. A. Portnoy, and J. A. Swanson.
1996.
Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes.
J. Biol. Chem.
271:7249-7252[Abstract/Free Full Text].
|
| 21.
|
Linden, R. M., and K. I. Berns.
1997.
Site-specific integration by adeno-associated virus: a basis for a potential gene-therapy vector.
Gene Ther.
4:4-5[Medline].
|
| 22.
|
Linden, R. M.,
E. Winocour, and K. I. Berns.
1996.
The recombination signals for adeno-associated virus site-specific integration.
Proc. Natl. Acad. Sci. USA
93:7966-7972[Abstract/Free Full Text].
|
| 23.
|
Linden, R. M.,
P. Ward,
C. Giraud,
E. Winocour, and K. I. Berns.
1996.
Site-specific integration by adeno-associated virus.
Proc. Natl. Acad. Sci. USA
93:11288-11294[Abstract/Free Full Text].
|
| 24.
|
Nabel, G. J.,
E. G. Nabel,
Z.-H. Yang,
B. A. Fox,
G. E. Plautz,
X. Gao,
L. Huang,
S. Shu,
D. Gordon, and A. E. Chang.
1993.
Direct gene transfer with DNA-liposome complexes in melanoma: expression, biological activity and lack of toxicity in humans.
Proc. Natl. Acad. Sci. USA
90:11307-11311[Abstract/Free Full Text].
|
| 25.
|
Prasad, K. M. R., and J. P. Trempe.
1995.
The adeno-associated virus Rep78 protein is covalently linked to viral DNA in a preformed virion.
Virology
214:360-370[Medline].
|
| 26.
|
Prasad, K. M. R.,
C. Zhou, and J. P. Trempe.
1997.
Characterization of the Rep78/adeno-associated virus complex.
Virology
229:183-192[Medline].
|
| 27.
|
Samulski, R. J.
1993.
Adeno-associated virus: integration at a specific chromosomal locus.
Curr. Opin. Genet. Dev.
3:74-80[Medline].
|
| 28.
|
Samulski, R. J.,
L. S. Chang, and T. Shenk.
1987.
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study in vitro replication.
J. Virol.
61:3096-3101[Abstract/Free Full Text].
|
| 29.
|
Samulski, R. J.,
X. Zhu,
X. Xiao,
J. D. Brook,
D. E. Housman,
N. Epstein, and L. A. Hunter.
1991.
Targeted integration of adeno-associated virus (AAV) into human chromosome 19.
EMBO J.
10:3941-3950[Medline]. (Erratum, 11:1228, 1992.)
|
| 30.
|
Sells, M. A.,
J. Li, and J. Chernoff.
1995.
Delivery of protein into cells using polycationic liposomes.
BioTechniques
19:72-78[Medline].
|
| 31.
|
Shelling, A. N., and M. G. Smith.
1994.
Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycine resistance gene.
Gene Ther.
1:165-169[Medline].
|
| 32.
|
Snyder, R. O.,
D.-S. Im,
T. Ni,
X. Xiao,
R. J. Samulski, and N. Muzyczka.
1993.
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein.
J. Virol.
67:6096-6104[Abstract/Free Full Text].
|
| 33.
|
Srivastava, A.,
E. W. Lusby, and K. I. Berns.
1983.
Nucleotide sequence and organization of the adeno-associated virus 2 genome.
J. Virol.
45:555-564[Abstract/Free Full Text].
|
| 34.
|
Surosky, R. T.,
M. Urabe,
S. G. Godwin,
S. A. McQuiston,
G. J. Kurtzman,
K. Ozawa, and G. Natsoulis.
1997.
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome.
J. Virol.
71:7951-7959[Abstract].
|
| 35.
|
Templeton, N. S.,
D. D. Lasic,
P. M. Frederik,
H. H. Strey,
D. D. Roberts, and G. N. Pavlakis.
1997.
Improved DNA:liposome complexes for increased systemic delivery and gene expression.
Nature Biotechnol.
15:647-652[Medline].
|
| 36.
|
Toniatti, C.,
A. Demartis,
P. Monaci,
A. Nicosia, and G. Ciliberto.
1990.
Synergistic transactivation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.
EMBO J.
9:4467-4475[Medline].
|
| 37.
|
Weitzman, M. D.,
S. R. Kyostio,
R. M. Kotin, and R. A. Owens.
1994.
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.
Proc. Natl. Acad. Sci. USA
91:5808-5812[Abstract/Free Full Text].
|
| 38.
|
Wobbe, C. R.,
F. Dean,
L. Weissbach, and J. Hurwitz.
1985.
In vitro replication of duplex circular DNA containing the simian virus SV40 DNA origin site.
Proc. Natl. Acad. Sci. USA
82:5710-5714[Abstract/Free Full Text].
|
| 39.
|
Yang, C. C.,
X. Xiao,
X. Zhu,
D. C. Ansardi,
N. D. Epstein,
M. R. Frey,
A. G. Matera, and R. J. Samulski.
1997.
Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro.
J. Virol.
71:9231-9247[Abstract].
|
| 40.
|
Yoemitsu, Y.,
Y. Kaneda,
A. Muraishi,
T. Yoshizumi,
K. Sugimachi, and K. Sueishi.
1997.
HVJ (Sendai virus)-cationic liposomes: a novel and potentially effective liposome-mediated technique for gene transfer to the airway epithelium.
Gene Ther.
4:631-638[Medline].
|
Journal of Virology, September 1998, p. 7653-7658, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
McAlister, V. J., Owens, R. A.
(2007). Preferential Integration of Adeno-Associated Virus Type 2 into a Polypyrimidine/Polypurine-Rich Region within AAVS1. J. Virol.
81: 9718-9726
[Abstract]
[Full Text]
-
Wang, H., Lieber, A.
(2006). A Helper-Dependent Capsid-Modified Adenovirus Vector Expressing Adeno-Associated Virus Rep78 Mediates Site-Specific Integration of a 27-Kilobase Transgene Cassette. J. Virol.
80: 11699-11709
[Abstract]
[Full Text]
-
Duizer, E., Schwab, K. J., Neill, F. H., Atmar, R. L., Koopmans, M. P. G., Estes, M. K.
(2004). Laboratory efforts to cultivate noroviruses. J. Gen. Virol.
85: 79-87
[Abstract]
[Full Text]
-
Urabe, M., Kogure, K., Kume, A., Sato, Y., Tobita, K., Ozawa, K.
(2003). Positive and negative effects of adeno-associated virus Rep on AAVS1-targeted integration. J. Gen. Virol.
84: 2127-2132
[Abstract]
[Full Text]
-
Philpott, N. J., Gomos, J., Berns, K. I., Falck-Pedersen, E.
(2002). A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc. Natl. Acad. Sci. USA
99: 12381-12385
[Abstract]
[Full Text]
-
Wang, Y., Camp, S. M., Niwano, M., Shen, X., Bakowska, J. C., Breakefield, X. O., Allen, P. D.
(2002). Herpes Simplex Virus Type 1/Adeno-Associated Virus rep+ Hybrid Amplicon Vector Improves the Stability of Transgene Expression in Human Cells by Site-Specific Integration. J. Virol.
76: 7150-7162
[Abstract]
[Full Text]
-
Philpott, N. J., Giraud-Wali, C., Dupuis, C., Gomos, J., Hamilton, H., Berns, K. I., Falck-Pedersen, E.
(2002). Efficient Integration of Recombinant Adeno-Associated Virus DNA Vectors Requires a p5-rep Sequence in cis. J. Virol.
76: 5411-5421
[Abstract]
[Full Text]
-
Young, S. M. Jr., Samulski, R. J.
(2001). Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc. Natl. Acad. Sci. USA
10.1073/pnas.241508998v1
[Abstract]
[Full Text]
-
Ponnazhagan, S., Curiel, D. T., Shaw, D. R., Alvarez, R. D., Siegal, G. P.
(2001). Adeno-associated Virus for Cancer Gene Therapy. Cancer Res.
61: 6313-6321
[Full Text]
-
Satoh, W., Hirai, Y., Tamayose, K., Shimada, T.
(2000). Site-Specific Integration of an Adeno-Associated Virus Vector Plasmid Mediated by Regulated Expression of Rep Based on Cre-loxP Recombination. J. Virol.
74: 10631-10638
[Abstract]
[Full Text]
-
Lamartina, S., Ciliberto, G., Toniatti, C.
(2000). Selective Cleavage of AAVS1 Substrates by the Adeno-Associated Virus Type 2 Rep68 Protein Is Dependent on Topological and Sequence Constraints. J. Virol.
74: 8831-8842
[Abstract]
[Full Text]
-
Lamartina, S., Sporeno, E., Fattori, E., Toniatti, C.
(2000). Characteristics of the Adeno-Associated Virus Preintegration Site in Human Chromosome 19: Open Chromatin Conformation and Transcription-Competent Environment. J. Virol.
74: 7671-7677
[Abstract]
[Full Text]
-
Cathomen, T., Collete, D., Weitzman, M. D.
(2000). A Chimeric Protein Containing the N Terminus of the Adeno-Associated Virus Rep Protein Recognizes Its Target Site in an In Vivo Assay. J. Virol.
74: 2372-2382
[Abstract]
[Full Text]
-
Rinaudo, D., Lamartina, S., Roscilli, G., Ciliberto, G., Toniatti, C.
(2000). Conditional Site-Specific Integration into Human Chromosome 19 by Using a Ligand-Dependent Chimeric Adeno-Associated Virus/Rep Protein. J. Virol.
74: 281-294
[Abstract]
[Full Text]
-
Gavin, D. K., Young, S. M. Jr., Xiao, W., Temple, B., Abernathy, C. R., Pereira, D. J., Muzyczka, N., Samulski, R. J.
(1999). Charge-to-Alanine Mutagenesis of the Adeno-Associated Virus Type 2 Rep78/68 Proteins Yields Temperature-Sensitive and Magnesium-Dependent Variants. J. Virol.
73: 9433-9445
[Abstract]
[Full Text]
-
Recchia, A., Parks, R. J., Lamartina, S., Toniatti, C., Pieroni, L., Palombo, F., Ciliberto, G., Graham, F. L., Cortese, R., La Monica, N., Colloca, S.
(1999). Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. USA
96: 2615-2620
[Abstract]
[Full Text]
-
Rizzuto, G., Gorgoni, B., Cappelletti, M., Lazzaro, D., Gloaguen, I., Poli, V., Sgura, A., Cimini, D., Ciliberto, G., Cortese, R., Fattori, E., La Monica, N.
(1999). Development of Animal Models for Adeno-Associated Virus Site-Specific Integration. J. Virol.
73: 2517-2526
[Abstract]
[Full Text]
-
Young, S. M. Jr., Samulski, R. J.
(2001). Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc. Natl. Acad. Sci. USA
98: 13525-13530
[Abstract]
[Full Text]